Journals / E Journal of Cardiovascular Medicine / 2022 / Cilt: 10 - Sayı: 1

The Relationship Between N-Terminal Pro-Brain Natriuretic Peptide Level and Left Ventricular Metabolic Index in Patients with Heart Failure with Mildly Reduced Ejection Fraction

Pages
4–11
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this patient group, especially female gender and renal dysfunction may be risk factors for high LVMI.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: It has been determined that mortality and hospitalization rates due to cardiovascular diseases are higher in patients with left ventricular hypertrophy (LVH).
📊
Key Findings & Data:Materials and Methods: Between January 2018 and October 2021, 213 patients diagnosed with heart failure with mildly reduced ejection fraction were included in the study.
💡
Conclusion & Impact:In this patient group, especially female gender and renal dysfunction may be risk factors for high LVMI.
🔬Design:Research Article
📍Scope:2018 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: It has been determined that mortality and hospitalization rates due to cardiovascular diseases are higher in patients with left ventricular hypertrophy (LVH). In addition, LVH has been shown to be an independent risk factor for heart failure (HF). Previous studies in this area have focused more on preserved and low ejection fraction HF. Therefore, we aimed to contribute to the literature by investigating the relationship between N-terminal pro-brain natriuretic peptide level (NT-proBNP) and left ventricular metabolic index (LVMI) in heart failure with mildly reduced ejection fraction (HFmrEF). Materials and Methods: Between January 2018 and October 2021, 213 patients diagnosed with heart failure with mildly reduced ejection fraction were included in the study. This study was designed as cross-sectional. The patients were divided into two groups according to their gender, as those with normal and abnormal LVMI. Pearson’s correlations were used to assess the correlations between LVMI and NT-proBNP. A ROC curve was plotted to determine the diagnostic reliability of plasma concentration of NT-proBNP on LVMI. Results: There were 90 patients in Group 1 (patients with normal LVMI) and 123 patients in Group 2 (patients with high LVMI). The mean LVMI value was 94.37 (±11.10) g/m2 in Group 1 and 119.64 (±15.90) g/m2 in Group 2. The mean NT proBNP level was found to be 941.57 (±1190.81) pg/ml. NT-proBNP levels were statistically significantly higher in Group 2 than in Group 1 (1138.49±1330.7 vs. 672.46±907.52, p=0.005). The relationship between NT-proBNP (941.57±1190.81 pg/mL) levels and LVMI (108.96±18.81 g/m2 ) was tested by the Pearson correlation. A moderate, positive and significant relationship was found between these variables [r (211) = 0.368, p342 pg/mL had 57% sensitivity and 58% specificity [receiver operating characteristic (ROC) area under curve: 0.620, 95% CI: 0.544-0.695, p=0.003] for determining LVMI. Conclusion: In patients with heart failure with mildly reduced ejection fraction, high NT-proBNP levels can predict LVMI elevation, which is an indicator of LVH. In this patient group, especially female gender and renal dysfunction may be risk factors for high LVMI.

🔖

Cite This Article

KIŞ, M., ŞENÖZ, O., GÜZEL, T. (2022). The Relationship Between N-Terminal Pro-Brain Natriuretic Peptide Level and Left Ventricular Metabolic Index in Patients with Heart Failure with Mildly Reduced Ejection Fraction. E Journal of Cardiovascular Medicine, Cilt: 10 - Sayı: 1, 4–11. https://ajindex.com/articles/498207

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Gupta DK, Wang TJ. Natriuretic peptides and cardiometabolic. Health Circ J 2015;79:1647-55
  2. Santaguida PL, Don-Wauchope AC, Oremus M, et al. BNP and NT-probNP as prognostic markers in persons with acute decompensated heart failure: A systematic review. Heart Fail Rev 2014;19:453-70
  3. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Kardiol Pol 2016;74:1037-147
  4. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599-726
  5. Djordjevic T, Arena R, Guazzi M, Popovic D. Prognostic value of NTPro Brain natriuretic peptide during exercise recovery in ıschemic heart failure of reduced, midrange, and preserved ejection fraction. J Cardiopulm Rehabil Prev 2021;41:282-7
  6. Markus MRP, de Freitas HFG, Chizzola PR, et al. Massa ventricular esquerda em portadores de insuficiência cardíaca. Arq Bras Cardiol 2004;83:227-31
  7. Gardin JM, McClelland R, Kitzman D, et al. M-mode echocardiographic predictors of six- to seven-year incidence of coronary heart disease, stroke, congestive heart failure, and mortality in an elderly cohort (the Cardiovascular Health Study). Am J Cardiol 2001;87:1051-7
  8. Gradman AH, Alfayoumi F. From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease. Prog Cardiovasc Dis 2006;48:326-41
  9. Cebeci E, Samancı NŞ, Uzun S, et al. Inflammation, left ventricular mass ındex and chronic renal failure in diabetic patients. Haseki Med Bull 2020;58:129-34
  10. Santosa YP, Tjandrawati A, Noormartany, et al. Comparison of pro B-natriuretic peptide in hypertensive patients with and without diastolic dysfunction. Acta Med Indones 2008;40:19-23
  11. İltümür K, Karabulut A, Toprak N. İzole diyastolik disfonksiyonda NtProbnp. Dicle Med J 2005;32:165-71
  12. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: A report from the American society of echocardiography's guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European association of echocardiography, a branch of the European society of cardiology. J Am Soc Echocardiogr 2005;18:1440-63
  13. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986;57:450-8
  14. Rørth R, Jhund PS, Yilmaz MB,